eNLife Research is building an AI-driven blood biomarker platform intended to detect Alzheimer’s disease up to 15 years before symptoms appear. Its platform analyses a panel of biomarkers and applies artificial intelligence to identify early signs of neurodegenerative disease progression. The company is also developing next-generation assays capable of tracking up to 100 biological markers for multiple forms of dementia and other disorders. eNLife plans to make tests available through routine diagnostic centres with results in two to five hours and aims to move its first diagnostic assay from prototype to clinical-grade validation. The startup is expanding its Bengaluru-based R&D team and is collaborating with several Indian research institutions to create India-specific biomarker datasets. Financially, eNLife recently raised a ₹6 crore seed round led by Piper Serica VC Fund to fund these efforts.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026